Newly-launched US biotech EQRx has big ambitions.
The company claims that it will create patent-protected medicines at dramatically lower prices for people, healthcare systems and society by re-engineering the process from drug discovery to patient delivery.
Its market-based solution for the rising cost of medicines is being put forward by Alexis Borisy, who is the chief executive of EXRx and co-founded Foundation Medicine and Blueprint Medicines (Nasdaq: BPMC).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze